Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety and Feasibility of Fasting While Receiving Chemotherapy

This study has been completed.
Information provided by:
King Fahad Medical City Identifier:
First received: September 19, 2008
Last updated: February 24, 2010
Last verified: February 2010
Fasting (refraining from eating and drinking) during the day is safe while receiving chemotherapy.


Study Type: Observational
Study Design: Observational Model: Case-Crossover
Time Perspective: Prospective
Official Title: Safety and Feasibility of Fasting While Receiving Chemotherapy

Further study details as provided by King Fahad Medical City:

Primary Outcome Measures:
  • Safety of fasting while receiving chemotherapy [ Time Frame: two months ]

Secondary Outcome Measures:
  • Effect of fasting on chemotherapy side effects [ Time Frame: two months ]

Enrollment: 12
Study Start Date: September 2008
Study Completion Date: March 2009
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Patients planning to observe fasting while receiving chemotherapy during the month of Ramadan


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Fasting patients who are schedulled to receive chemotherapy during the month of Ramadan

Inclusion Criteria:

  • Age > 18 years
  • Established diagnosis of cancer
  • Signed informed consent
  • Adequate CBC and chemistry to receive chemotherapy

Exclusion Criteria:

  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00757094

Saudi Arabia
King Fahad Medical City
Riyadh, Saudi Arabia, 11525
Sponsors and Collaborators
King Fahad Medical City
Principal Investigator: Ali SM Al-Shanqeeti, MD King Fahad Medical City